{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:29:29Z","timestamp":1788370169279,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"vor","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013410","name":"LivaNova Plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.yebeh.2023.109288","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:45:50Z","timestamp":1687221950000},"page":"109288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Patterns of utilization and cost of healthcare services and pharmacotherapy among patients with drug-resistant epilepsy during the two-year period before neurostimulation: A descriptive analysis of the journey to implantation based on analyses of a large United States healthcare claims database"],"prefix":"10.1016","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7675-6750","authenticated-orcid":false,"given":"Kathryn","family":"Evans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1396-412X","authenticated-orcid":false,"given":"Nicole","family":"Stamas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0787-2595","authenticated-orcid":false,"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5857-6254","authenticated-orcid":false,"given":"Vanessa","family":"Danielson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandi","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9280-6342","authenticated-orcid":false,"given":"Reginald","family":"Lassagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8833-4544","authenticated-orcid":false,"given":"Ariel","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.yebeh.2023.109288_b0005","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.yebeh.2023.109288_b0010","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.yebeh.2023.109288_b0015","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1528-1167.2008.01579.x","article-title":"The prevalence of epilepsy and pharmacoresistant epilepsy in adults: a population-based study in a Western European country","volume":"49","author":"Picot","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109288_b0020","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.yebeh.2013.09.046","article-title":"Healthcare utilization and costs in adults with stable and uncontrolled epilepsy","volume":"31","author":"Cramer","year":"2014","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2023.109288_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108319","article-title":"A journey into the unknown: An ethnographic examination of drug-resistant epilepsy treatment and management in the United States","volume":"124","author":"Watson","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"4","key":"10.1016\/j.yebeh.2023.109288_b0030","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s13760-016-0622-5","article-title":"Factors affecting the quality of life in drug-resistant epilepsy patients","volume":"116","author":"Akdemir","year":"2016","journal-title":"Acta Neurol Belg"},{"issue":"4","key":"10.1016\/j.yebeh.2023.109288_b0035","doi-asserted-by":"crossref","first-page":"216","DOI":"10.17749\/2077-8333\/epi.par.con.2020.044","article-title":"Quality of life and its determinants in patients with drug resistant focal epilepsy","volume":"12","author":"Malyshev","year":"2021","journal-title":"Epilepsy Paroxysmal Cond"},{"issue":"4","key":"10.1016\/j.yebeh.2023.109288_b0040","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.nrl.2012.04.012","article-title":"Quality of life and economic impact of refractory epilepsy in Spain: the ESPERA study","volume":"28","author":"Villanueva","year":"2013","journal-title":"Neurologia"},{"key":"10.1016\/j.yebeh.2023.109288_b0045","unstructured":"US Food & Drug Administration. Premarket approval: VNS therapy system. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma.cfm?id=P970003S207. Updated December 5, 2022. Accessed on January 24, 2023."},{"key":"10.1016\/j.yebeh.2023.109288_b0050","unstructured":"US Food & Drug Administration. Premarket approval: Neuropace RNS System. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma.cfm?id=P100026. Updated December 5, 2022. Accessed on January 24, 2023."},{"key":"10.1016\/j.yebeh.2023.109288_b0055","unstructured":"NeuroPace Receives IDE Approval to Initiate NAUTILUS Pivotal Study of its RNS System for Idiopathic Generalized Epilepsy. Neuropace. https:\/\/neuropace.com\/press-release\/neuropace-receives-ide-approval-to-initiate-nautilus-pivotal-study-of-its-rns-system-for-idiopathic-generalized-epilepsy\/. Published 2021. Accessed December 14, 2022."},{"issue":"4","key":"10.1016\/j.yebeh.2023.109288_b0060","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3390\/brainsci8040049","article-title":"Diagnosis and surgical treatment of drug-resistant epilepsy","volume":"8","author":"Anyanwu","year":"2018","journal-title":"Brain Sci"},{"issue":"4","key":"10.1016\/j.yebeh.2023.109288_b0065","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.14336\/AD.2021.0211","article-title":"Neuromodulation in Drug Resistant Epilepsy","volume":"12","author":"Rincon","year":"2021","journal-title":"Aging Dis"},{"key":"10.1016\/j.yebeh.2023.109288_b0070","unstructured":"US Food & Drug Administration. Premarket approval: Medtronic DBS Therapy for Epilepsy. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma.cfm?id=P100026. Updated December 5, 2022. Accessed on January 25, 2023."},{"issue":"4","key":"10.1016\/j.yebeh.2023.109288_b0075","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.seizure.2008.10.012","article-title":"Vagus nerve stimulation: longitudinal follow-up of patients treated for 5 years","volume":"18","author":"Kuba","year":"2009","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.yebeh.2023.109288_b0080","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/14737175.2019.1554433","article-title":"Neuromodulation - science and practice in epilepsy: vagus nerve stimulation, thalamic deep brain stimulation, and responsive neurostimulation","volume":"19","author":"Markert","year":"2019","journal-title":"Expert Rev Neurother"},{"issue":"9","key":"10.1016\/j.yebeh.2023.109288_b0085","doi-asserted-by":"crossref","first-page":"e1244","DOI":"10.1212\/WNL.0000000000010154","article-title":"Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy","volume":"95","author":"Nair","year":"2020","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.yebeh.2023.109288_b0090","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/epi.16593","article-title":"Real-world experience with direct brain-responsive neurostimulation for focal onset seizures","volume":"61","author":"Razavi","year":"2020","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.yebeh.2023.109288_b0095","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/epi.16572","article-title":"Deciphering the surgical treatment gap for drug-resistant epilepsy (DRE): a literature review","volume":"61","author":"Solli","year":"2020","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.yebeh.2023.109288_b0100","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1017\/S109285290000849X","article-title":"Understanding the delay before epilepsy surgery: who develops intractable focal epilepsy and when?","volume":"9","author":"Berg","year":"2004","journal-title":"CNS Spectr"},{"issue":"October","key":"10.1016\/j.yebeh.2023.109288_b0105","first-page":"36","article-title":"Diagnostic & treatment delay in temporal lobe epilepsy","author":"Mazumder","year":"2021","journal-title":"Pract Neurol (Fort Wash Pa)"},{"issue":"2","key":"10.1016\/j.yebeh.2023.109288_b0110","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1017\/S1092852900008464","article-title":"The consequences of uncontrolled epilepsy","volume":"9","author":"Sperling","year":"2004","journal-title":"CNS Spectr"},{"issue":"23","key":"10.1016\/j.yebeh.2023.109288_b0115","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1212\/WNL.0000000000003407","article-title":"What can we do for people with drug-resistant epilepsy? The 2016 Wartenberg Lecture","volume":"87","author":"Engel","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2023.109288_b0120","unstructured":"IBM Watson Health. IBM MarketScan Research Databases for life sciences. July 2021. Accessed on January 25, 2023. Accessed at: https:\/\/www.ibm.com\/downloads\/cas\/OWZWJ0QO."},{"issue":"2","key":"10.1016\/j.yebeh.2023.109288_b0125","doi-asserted-by":"crossref","first-page":"e220320","DOI":"10.1001\/jamanetworkopen.2022.0320","article-title":"Trends in Disenrollment and Reenrollment Within US Commercial Health Insurance Plans, 2006\u20132018","volume":"5","author":"Fang","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.yebeh.2023.109288_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108865","article-title":"Incidence of mental health conditions by seizure control among adults with epilepsy in the United States","volume":"134","author":"Schabert","year":"2022","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2023.109288_b0135","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.seizure.2022.10.019","article-title":"Psychiatric symptoms predict drug-resistant epilepsy in newly treated patients","volume":"103","author":"Zhong","year":"2022","journal-title":"Seizure"},{"issue":"8","key":"10.1016\/j.yebeh.2023.109288_b0140","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.eplepsyres.2014.06.008","article-title":"Low vitamin D levels are common in patients with epilepsy","volume":"108","author":"Teagarden","year":"2014","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2023.109288_b0145","doi-asserted-by":"crossref","first-page":"1042168","DOI":"10.3389\/fneur.2022.1042168","article-title":"Response to subsequent antiseizure medications after first antiseizure medication failure in newly diagnosed epilepsy","volume":"13","author":"Hersi","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.yebeh.2023.109288_b0150","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.yebeh.2017.11.006","article-title":"Quality of life in adults with epilepsy is associated with anticonvulsant polypharmacy independent of seizure status","volume":"78","author":"Alexander","year":"2018","journal-title":"Epilepsy Behav"},{"issue":"1","key":"10.1016\/j.yebeh.2023.109288_b0155","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1055\/s-0040-1712074","article-title":"Antiepileptic drugs, polypharmacy, and quality of life in people living with epilepsy managed in general practice","volume":"06","author":"Moran","year":"2020","journal-title":"Int J Epilepsy"},{"issue":"3","key":"10.1016\/j.yebeh.2023.109288_b0160","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.yebeh.2004.01.006","article-title":"Improvement in seizure control and quality of life in medically refractory epilepsy patients converted from polypharmacy to monotherapy","volume":"5","author":"Pirio Richardson","year":"2004","journal-title":"Epilepsy Behav"},{"issue":"2","key":"10.1016\/j.yebeh.2023.109288_b0165","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/epi.17153","article-title":"Association between antiseizure medications and quality of life in epilepsy: A mediation analysis","volume":"63","author":"Wang","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109288_b0170","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.17714.1","article-title":"Presurgical epilepsy evaluation and epilepsy surgery","volume":"8","author":"Baumgartner","year":"2019","journal-title":"F1000Res"},{"key":"10.1016\/j.yebeh.2023.109288_b0175","unstructured":"Cedars-Sinai. Vagus nerve stimulator. https:\/\/www.cedars-sinai.org\/health-library\/tests-and-procedures\/v\/vagus-nerve-stimulator.html. Accessed July 15, 2022."},{"key":"10.1016\/j.yebeh.2023.109288_b0180","unstructured":"Epilepsy Foundation. Epilepsy for parents and caregivers. https:\/\/www.epilepsy.com\/parents-and-caregivers. Accessed July 15, 2022."},{"key":"10.1016\/j.yebeh.2023.109288_b0185","unstructured":"Mayfield Brain & Spine. Epilepsy surgery. https:\/\/mayfieldclinic.com\/pe-epilepsysurg.htm. Updated January 2021. Accessed July 15, 2022."},{"key":"10.1016\/j.yebeh.2023.109288_b0190","unstructured":"Royal Children's Hospital Melbourne. Vagus nerve stimulation. https:\/\/www.rch.org.au\/neurology\/patient_information\/vagus_nerve_stimulation\/. Accessed July 15, 2022."},{"key":"10.1016\/j.yebeh.2023.109288_b0195","unstructured":"UCSF Benioff Children's Hospitals. Epilepsy Presurgical Evaluation. https:\/\/www.ucsfbenioffchildrens.org\/education\/epilepsy-presurgical-evaluation. Accessed July 15, 2022."},{"issue":"1","key":"10.1016\/j.yebeh.2023.109288_b0200","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1080\/13696998.2022.2148680","volume":"25","author":"Vincent","year":"2022","journal-title":"J Med Econ"},{"issue":"9","key":"10.1016\/j.yebeh.2023.109288_b0205","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/cns.13690","article-title":"Potential surgical therapies for drug-resistant focal epilepsy","volume":"27","author":"Shan","year":"2021","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.yebeh.2023.109288_b0210","unstructured":"US Centers for Medicare and Medicaid Services. NHE Fact Sheet. https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/NationalHealthExpendData\/NHE-Fact-Sheet. Updated August 12, 2022. Accessed December 6, 2022."},{"issue":"1","key":"10.1016\/j.yebeh.2023.109288_b0215","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.yebeh.2008.02.003","article-title":"A survey of neurologists' views on epilepsy surgery and medically refractory epilepsy","volume":"13","author":"Hakimi","year":"2008","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2023.109288_b0220","unstructured":"Greenwood J, Thomas B, Lopez M, et al. Epilepsy advanced practice providers identify barriers to epilepsy surgery: a survey study [Abstract]. https:\/\/www.aesnet.org\/abstractslisting\/epilepsy-advanced-practice-providers-identify-barriers-to-epilepsy-surgery--a-survey-study. Updated November 22, 2021. Accessed."},{"issue":"5","key":"10.1016\/j.yebeh.2023.109288_b0225","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/epi.17208","article-title":"Hospital costs associated with vagus nerve stimulation and medical treatment in pediatric patients with refractory epilepsy","volume":"63","author":"Zhang","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2023.109288_b0230","first-page":"22","article-title":"Neuromodulation for treatment-resistant depression","volume":"4","author":"Holtzheimer","year":"2012","journal-title":"F1000 Medicine Rep"},{"key":"10.1016\/j.yebeh.2023.109288_b0235","unstructured":"LivaNova PLC. VNS Therapy\u2122 System Depression Physician\u2019s Manual. https:\/\/dynamic.cyberonics.com\/manuals\/emanual_download.asp?lang=English-US&docid=%7BF402161D-23A5-4A11-B26F-DB420E28F19C%7D. Published 2022. Accessed December 6, 2022."}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550502300207X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550502300207X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:51:58Z","timestamp":1782496318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152550502300207X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":47,"alternative-id":["S152550502300207X"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2023.109288","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of utilization and cost of healthcare services and pharmacotherapy among patients with drug-resistant epilepsy during the two-year period before neurostimulation: A descriptive analysis of the journey to implantation based on analyses of a large United States healthcare claims database","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2023.109288","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 LivaNova. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109288"}}